Navigation Links
Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works
Date:4/15/2014

CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery and in the process have found a potentially less toxic way to fight invasive fungal infections, which kill about 1.5 million people a year. The researchers say they now understand the mechanism of action of amphotericin, an antifungal drug that has been in use for more than 50 years even though it is nearly as toxic to human cells as it is to the microbes it attacks.

A report of the new findings appears in Nature Chemical Biology.

"Invasive fungal infections are a very important unmet medical need," said University of Illinois and Howard Hughes Medical Institute chemistry professor Martin Burke, who led the study with chemistry professor Chad Rienstra. "There are about 3 million cases per year and what's striking is that, even in 2014, half the patients who come into the hospital with an invasive fungal infection in their blood die."

More people are killed by invasive fungal infections than by malaria or tuberculosis, Burke said.

Amphotericin (am-foe-TEHR-ih-sin) is the most effective broad-spectrum antifungal drug available, Burke said. But its use is limited by its toxicity to human cells.

"When I was a medical student, they used to call it 'amphoterrible' in the clinic because it has very powerful side effects," he said. "And so you're stuck between having the fungus kill the patient, versus using too much amphotericin, which kills the patient."

Scientists have long sought to make amphotericin less toxic, but have been hindered by an obvious problem: Because it is so hard to study, no one knew exactly how it worked.

"This molecule is one of the most challenging to work with because it has a very complex structure, is poorly soluble and is sensitive to light, oxygen and acid," Burke said.

Amphotericin also interacts with membranes, which are notoriously difficult to study. Many labs, including Burke's, have tried to figure out the three-dimensional structure of amphotericin by crystallizing it, a standard technique. So far, all attempts have failed.

So the team turned to one of the most powerful tools for studying non-crystalline samples: solid-state nuclear magnetic resonance (NMR) spectroscopy, which measures how atomic nuclei respond to changes in a magnetic field.

"NMR is a great technique for detecting signals and interpreting the structural properties of molecules in solution," said Rienstra, who led the NMR work with graduate students Mary Clay and Tom Anderson. But few labs use it to track interactions between small molecules in membranes, he said. "We developed several new NMR experiments to study amphotericin in the presence of membranes."

Previous studies had found evidence that amphotericin opens up ion channels in membranes, perhaps making them more leaky to charged atoms that could disrupt a cell. Most scientists assumed that this was the drug's main mode of action.

But the evidence also suggested that amphotericin interacted with sterols, such as cholesterol in animal cells and ergosterol in yeast. Rienstra and Burke focused on amphotericin's influence on sterols, hypothesizing that this might be a key to its toxicity.

The initial NMR data supported this idea, indicating that very little of the drug less than 5 percent actually formed channels in membranes. Using NMR and other experimental tools, the Rienstra/Burke team found that most of the amphotericin aggregates on the exterior of membranes, extracting sterols out of membranes like a sponge. Cell death follows soon after.

"For over 50 years, the mechanism by which amphotericin kills cells has remained a mystery," Burke said. "But we are finally seeing the fog start to clear. This new understanding allows us to focus on how to make this molecule less toxic to human cells."

In a separate study published in the Journal of the American Chemical Society, Burke and his colleagues appear to have accomplished just that. They developed a derivative of amphotericin that, at least in cell culture, binds to ergosterol in yeast but not to human cholesterol.

"We are very excited about this discovery," Burke said. "But a great deal of work lies ahead to see if this compound has the potential to serve as a less toxic treatment for fungal infections in human patients. At this point, we just have a very promising compound. Most importantly, thanks to the collaboration between these two labs, we now know where to look for solutions to this longstanding problem."

Preclinical trials of the new compound have begun, the researchers said.


'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Related medicine news :

1. Global Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural etc)- Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
2. IBN discovers human neural stem cells with tumor targeting ability
3. Rutgers team discovers novel approach to stimulate immune cells
4. UZH research team discovers the origins of key immune cells
5. Yale team discovers how stress and depression can shrink the brain
6. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
7. Penn-Temple team discovers gatekeeper for maintaining health of cell energy source
8. Aldrich Materials Science discovers liquid-free preparation of metal organic frameworks
9. U-M sibling study discovers genetic region linked to control of key blood-clotting protein
10. Kwiksure Discovers Uses and Limitations of Vehicle GPS in Hong Kong
11. Its the way you tell em: Study discovers how the brain controls accents and impersonations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... HOUSTON, Texas (PRWEB) , ... September 22, 2017 ... ... leading network of independent freestanding emergency rooms is celebrating the one year anniversary ... anniversary of our facility opening,” said Dr. Otinwa, Facility Medical Director of First ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... products at customers’ doorstep. According to Smart Mart, customers can now order vegetable, ... offer wearable, and customers can find clothing at discounted prices. Apart from this, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: